AAIC 2017 | What’s next for intepirdine

Marwan Sabbagh, MD, from Barrow Neurological Institute, Phoenix, AZ provides us with the lastest news on intepirdine. The MINDSET study (NCT02585934), a study evaluating intepirdine in subjects with mild to moderate Alzheimer’s disease on Donepezil is currently in the Phase III stage, with results expected later this year. Dr Sabbagh is optimistic that intepirdine will be the next drug to be licenced for Alzheimer’s. He is particularly excited about expanding the use of intepirdine into the lewy body dementia space, and seeing what effects it may have in this cohort of patients. This interview was recorded at the Alzheimer’s Association International Conference (AAIC) 2017, London, UK.